MarketPulse

pharmaceutical sector

3 articles
The Motley FoolThe Motley Fool··Jack Delaney

Bristol Myers Squibb Offers Dividend Appeal, But Patent Cliff Looms Large

Bristol Myers Squibb trades at attractive 9.5x forward P/E with 4.2% yield and 17 years of dividend hikes, but faces revenue declines and patent expiration risks.
BMYCELGrJNJMRKvalue investingdividend stocks
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks for Long-Term Investors

Eli Lilly's GLP-1 success masks valuation risks; P/E of 44 leaves little room for competitive pressure and patent cliff execution.
PFELLYNVOGLP-1 drugsgeneric competition
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Regencell's 21,000% Surge Masks Fundamental Risks in Unproven Biotech

Regencell Bioscience surged 21,000% despite zero revenue and no approved products, exemplifying speculative excess that investors should avoid.
PFERGCpenny stockdrug development